RAMOT at Tel Aviv University Ltd.

Cell Therapy for Diabetes: Expansion and re-differentiation of adult human pancreatic islet cells for transplantation

Posted by RAMOT at Tel Aviv University Ltd.Responsive · Innovative Products and Technologies · Israel

Summary of the technology

Prof. Efrat has developed a protocol for re-differentiating human beta cells after expansion; this can be explained by the open chromatin structure around beta-cell-specific genes that is retained in these cells. Thus, the cells can be expanded and then redifferentiated to beta cells to provide an expanded number of functional insulin producing cells. The entire process is performed in defined media.
Project ID : 10-2007-107

The Technology

Prof. Efrat has developed a protocol for re-differentiating human beta cells after expansion; this can be explained by the open chromatin structure around beta-cell-specific genes that is retained in these cells. Thus, the cells can be expanded and then redifferentiated to beta cells to provide an expanded number of functional insulin producing cells. The entire process is performed in xeno-free defined media.

Applications

Expansion of functional islet cells from single cadaveric donors for transplantation into multiple recipients for the treatment of diabetes and as a valuable tool for drug screening (organ-in-a tube).

Advantages

· Adult tissue source

· Growth in defined media

· No gene modification

· Expansion of over 65,000 fold (within 4 months)

Stage of Development

  • Beta-cell labeling with a fluorescent protein demonstrates replication of cells derived from islet beta cells. 40% of replicating cells are derived from beta cells. Fluorescent cells can be sorted and expanded in pure cultures.
  • Replication is accompanied by a decrease in expression of key beta-cell genes
  • Cell dedifferentiation and proliferation in vitro correlate with reactivation of the NOTCH pathway. Inhibition of HES1 expression using shRNA during culture initiation results in reduced β-cell replication and dedifferentiation, suggesting that HES1 inhibition may also affect cell redifferentiation following expansion.
  • Shift to differentiation conditions following expansion results in restoration of beta-cell gene expression and insulin production.
  • In vivo analyses demonstrated the ability of the redifferentiated cells to replace β-cell function in hyperglycemic immunodeficient mice.

These findings demonstrate the redifferentiation potential of ex vivo expanded beta-cell derived cells.


Project manager

Adi Elkeles
BD Manager

Project researchers

Shimon Efrat
T.A.U Tel Aviv University, Medicine-Sackler Faculty
Human Molecular Genetics

Related keywords

  • Medicine, Human Health
  • Medical Technology / Biomedical Engineering
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Microbiology Technology
  • Bioinformatics Technology
  • Micro- and Nanotechnology related to Biological sciences
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Bioinformatics Market
  • Therapeutic
  • Clinical Medicine
  • Pharmaceutical Indications
  • Life Sciences and Biotechnology
  • Stem Cells
  • Cell therapy
  • Pharmaceutical Indications
  • metabolic
  • Cell therapy

About RAMOT at Tel Aviv University Ltd.

Technology Transfer Office from Israel

Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.